Kwame Zaire is a distinguished authority in biotechnology manufacturing, bringing a wealth of experience in high-end electronics, production management, and the implementation of predictive maintenance protocols. His perspective is deeply rooted in the practical application of quality and safety standards within the fast-paced biopharmaceutical sector, where he monitors the transition from rigid legacy infrastructure to agile, innovative systems. By examining the shift toward single-use technologies, Kwame offers a unique viewpoint on how standardized bioreactor platforms are revolutionizing drug substance lines and operational efficiency. In this discussion, we explore the strategic move toward integrated bioproduction cycles, the economic impact of scaling from lab-bench models to massive commercial installations, and the forecasted growth of a market that is increasingly defined by flexibility and process intensification.
How is the widespread adoption of single-use technology fundamentally reshaping the production life cycle for biopharmaceutical companies compared to traditional stainless steel methods?
The shift toward single-use technology is about much more than just swapping out materials; it represents a complete overhaul of how we view operational agility and speed-to-market. In traditional setups, the heavy reliance on stainless steel and glass meant we were often bogged down by grueling cleaning schedules and the constant fear of cross-contamination between batches. Now, by integrating single-use systems across the entire cycle—from cell culture media and seed-train expansion to the final purification stages—manufacturers can pivot between different biologics with incredible ease. This flexibility is essential as biologics pipelines become more diverse, requiring us to move away from rigid, one-size-fits-all factories toward modular, digitally connected operations. There is a palpable sense of relief on the production floor when you realize that the intensive labor once dedicated to sterilization can now be funneled into process optimization and high-cell-density processing.
With the introduction of innovative platforms like the DynaDrive, what specific operational advantages and cost-saving opportunities are manufacturers seeing on the ground?
Platforms like the DynaDrive are essentially breaking the performance barriers that used to limit single-use systems, offering a level of scalability that was previously unthinkable. For instance, we are seeing these systems decrease overall production costs by up to 25% because they drastically reduce the amount of equipment, labor, and consumables required to run a site. When you look at the bench-scale 5L version, the workflow efficiency alone increases by 27% compared to traditional glass bioreactors, which is a massive win for labs trying to accelerate their development timelines. It is not just about the numbers, though; it is about the sensory experience of a more streamlined workspace where film performance and bag integrity are so reliable that technicians can focus on innovation rather than troubleshooting leaks. These technologies are becoming the standard because they allow both innovative pharma companies and contract manufacturers to run their operations with a precision that mimics the most advanced electronics assembly lines.
How are contract development and manufacturing organizations utilizing these high-capacity single-use systems to secure a competitive advantage in a crowded market?
Contract development and manufacturing organizations, or CDMOs, are really where the rubber meets the road for these technologies, as their entire business model depends on how efficiently they can run their operations. A great example of this is seeing major players like AGC Biologics in Japan adopting 5,000L systems to create some of the most advanced mammalian biomanufacturing capabilities in the region. We have also seen incredible results from WuXi Biologics in China, where their use of three 5,000L bioreactors during a commercial project led to a staggering 70% reduction in protein production costs. When a facility can report a 20% increase in yield per batch while simultaneously slashing costs, it sends a clear signal to the rest of the industry that single-use is the future. These organizations are betting on high-capacity, application-specific platforms to handle the complex demands of modern medicine, proving that you can achieve commercial scale without the massive footprint of a legacy steel plant.
In what ways does the transition from laboratory-scale development to full commercial manufacturing benefit from having a scalable family of single-use products?
The beauty of a scalable product family, ranging from a 5L benchtop unit all the way to a 5,000L commercial powerhouse, is the consistency it brings to the technology transfer process. In the past, moving a process from the lab to a large-scale facility often felt like starting over because the mixing dynamics and oxygen transfer rates would change so drastically. Modern suppliers are solving this by ensuring that the automated controls and process performance remain consistent across the entire family of products. This uniformity allows for a much smoother transition, reducing the technical risks that often haunt the move to commercial-scale drug substance lines. When the film performance and mixing logic are the same at every stage, the manufacturing team can confidently replicate the success of the laboratory environment on a much larger, more impactful scale.
Given that the market for single-use bioreactors is expected to nearly double in the coming years, what key trends do you believe will define the next era of bioproduction?
We are looking at a market that is projected to grow from $5.43 billion in 2026 to $9.58 billion by 2031, which is a significant compound annual growth rate of 12%. This growth is being fueled by an explosion in demand for biosimilars, vaccines, and the highly complex world of cell and gene therapies. We are seeing a move toward integrated, perfusion-ready systems and continuous manufacturing, which allow for a more constant and reliable output of medicine. The trend is clearly pointing toward higher-capacity, modular platforms that can be quickly deployed in multiproduct facilities to meet global health needs. Furthermore, as biopharma companies continue to outsource process development, CDMOs will remain the primary drivers of this adoption, investing in flexible facilities that can handle everything from viral vectors to recombinant proteins with minimal changeover time.
What is your forecast for the future of biopharmaceutical manufacturing facilities over the next decade?
I anticipate that the “facility of the future” will be almost entirely defined by its ability to be reconfigured in a matter of days rather than months, thanks to the maturation of single-use ecosystems. We will likely see a total convergence of digital connectivity and single-use hardware, where real-time data from automated controls ensures that every batch is optimized for the highest possible yield. The industry will move away from the massive, centralized “cathedrals of steel” toward decentralized, high-capacity modular sites that can be stood up quickly in any part of the world. As we continue to refine film integrity and oxygen transfer capabilities, the cost of life-saving biologics will continue to fall, making advanced therapies more accessible to patients globally. Ultimately, the standardization of these technologies will turn bioproduction into a highly predictable, high-output engine that mirrors the efficiency of the most advanced high-tech manufacturing sectors.
